LONDON, Oct 18 (Reuters) - AstraZeneca Plc lost a key European patent on its two-in-one asthma drug Symbicort on Thursday but the drugmaker said it did not expect the move to have an immediate impact ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

AstraZeneca, the UK-based maker of popular inhalers like Symbicort and Airsupra, announced Monday it plans to cap costs for patients using its inhalers in the U.S. at $35 per month starting June 1.

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: A U.S. flag stands next to the AstraZeneca logo during a signing event for documents related to a manufacturing site ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month ...

AstraZeneca ((AZN)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...

WILMINGTON, Del.--(BUSINESS WIRE)--Results from a US comparative effectiveness study of two maintenance treatment options for patients with a history of chronic obstructive pulmonary disease (COPD) ...

LONDON, June 4 (Reuters) - AstraZeneca Plc is seeking U.S. approval to market its asthma drug Symbicort as a treatment for young children, increasing the competitive pressure on GlaxoSmithKline Plc's ...

On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials ...